Source - SMW
Silence Therapeutics said it had been granted a patent by the European Patent Office for one if its RNA therapies.

The claims of European patent EP 1857547B would provide Silence with further protection for its chemical modification technology in Europe, the company said.

"These newly granted claims add further value to our intellectual property portfolio, and strengthen our patent position in Europe," chief executive Ali Mortazavi said.


At 8:24am: (LON:SLN) Silence Therapeutics PLC share price was +2.5p at 183.5p